Literature DB >> 24911352

Polymorphism in interleukin-7 receptor α gene is associated with faster CD4⁺ T-cell recovery after initiation of combination antiretroviral therapy.

Hans J Hartling1, Lise W Thørner, Christian Erikstrup, Lene H Harritshøj, Gitte Kronborg, Court Pedersen, Carsten S Larsen, Marie Helleberg, Jan Gerstoft, Niels Obel, Henrik Ullum, Susanne D Nielsen.   

Abstract

OBJECTIVES: To investigate single-nucleotide polymorphisms (SNPs) in the gene encoding interleukin-7 receptor α (IL7RA) as predictors for CD4⁺ T-cell change after initiation of combination antiretroviral therapy (cART) in HIV-infected whites.
DESIGN: SNPs in IL7RA were determined in the Danish HIV Cohort Study.
METHODS: CD4⁺ T-cell changes were estimated 6 months, 1, 2, and 5 years after initiation of cART in 1683 HIV-infected virally suppressed individuals. Five SNPs in IL7RA were examined as predictors for CD4⁺ T-cell change in the first (0-6 months after initiation of cART) and second phase (>6 months after initiation of cART) of immune recovery. Univariable and multivariable analyses including age, sex, calendar period, CD4⁺ nadir, and baseline CD4⁺ T-cell count and viral load as covariates were performed.
RESULTS: Individuals carrying two T-alleles in rs6897932 had faster CD4⁺ T-cell recovery compared with individuals carrying a C-allele in the first phase of immune recovery [mean CD4⁺ T-cell change, cells/μL (95% confidence interval), in TT: 177 (151-203), CT: 131 (119-143), CC: 141 (132-151), P = 0.018]. No isolated effect of rs6897932 on CD4⁺ T-cell change was found in the second phase of immune recovery; however, the initial difference in CD4⁺ T-cell recovery remained during 5 years. The effect was most pronounced in individuals above 40 years of age.
CONCLUSION: T-allele homozygosity in rs6897932 is a predictor for faster CD4⁺ T-cell recovery after initiation of cART in HIV-infected whites, however, only in the first phase of immune recovery.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24911352     DOI: 10.1097/QAD.0000000000000354

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  17 in total

Review 1.  IL7RA genetic variants differentially affect IL-7Rα expression and alternative splicing: a role in autoimmune and infectious diseases?

Authors:  Christian Lundtoft; Julia Seyfarth; Marc Jacobsen
Journal:  Genes Immun       Date:  2020-01-13       Impact factor: 2.676

2.  Association between the IL7R T244I polymorphism and multiple sclerosis risk: a meta analysis.

Authors:  Song Wu; Qian Liu; Ji-Min Zhu; Ming-Rui Wang; Jing Li; Mei-Guo Sun
Journal:  Neurol Sci       Date:  2016-05-17       Impact factor: 3.307

3.  Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients.

Authors:  M Guzmán-Fulgencio; J Berenguer; D Pineda-Tenor; M A Jiménez-Sousa; M García-Álvarez; T Aldámiz-Echevarria; A Carrero; C Diez; F Tejerina; S Vázquez; V Briz; S Resino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-19       Impact factor: 3.267

4.  Cryptococcosis-Associated Immune Reconstitution Inflammatory Syndrome Is Associated With Dysregulation of IL-7/IL-7 Receptor Signaling Pathway in T Cells and Monocyte Activation.

Authors:  Ngomu Akeem Akilimali; Daniel M Muema; Charles Specht; Christina C Chang; Mahomed-Yunus S Moosa; Stuart M Levitz; Sharon R Lewin; Martyn A French; Thumbi Ndungʼu
Journal:  J Acquir Immune Defic Syndr       Date:  2019-04-15       Impact factor: 3.731

5.  Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial.

Authors:  Jeffrey A Boatman; Jason V Baker; Sean Emery; Hansjakob Furrer; David M Mushatt; Dalibor Sedláček; Jens D Lundgren; James D Neaton
Journal:  J Acquir Immune Defic Syndr       Date:  2019-05-01       Impact factor: 3.731

6.  Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study.

Authors:  María Guzmán-Fulgencio; Juan Berenguer; María A Jiménez-Sousa; Daniel Pineda-Tenor; Teresa Aldámiz-Echevarria; Pilar García-Broncano; Ana Carrero; Mónica García-Álvarez; Francisco Tejerina; Cristina Diez; Sonia Vazquez-Morón; Salvador Resino
Journal:  J Transl Med       Date:  2015-06-30       Impact factor: 5.531

7.  Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin.

Authors:  Marco Gelpi; Hans J Hartling; Kristina Thorsteinsson; Jan Gerstoft; Henrik Ullum; Susanne D Nielsen
Journal:  BMC Infect Dis       Date:  2016-10-21       Impact factor: 3.090

8.  Investigating Factors Associated with Thymic Regeneration after Chemotherapy in Patients with Lymphoma.

Authors:  Dao-Ping Sun; Li Wang; Chong-Yang Ding; Jin-Hua Liang; Hua-Yuan Zhu; Yu-Jie Wu; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  Front Immunol       Date:  2016-12-27       Impact factor: 7.561

9.  Aberrant plasma IL-7 and soluble IL-7 receptor levels indicate impaired T-cell response to IL-7 in human tuberculosis.

Authors:  Christian Lundtoft; Anthony Afum-Adjei Awuah; Jens Rimpler; Kirstin Harling; Norman Nausch; Malte Kohns; Ernest Adankwah; Franziska Lang; Laura Olbrich; Ertan Mayatepek; Ellis Owusu-Dabo; Marc Jacobsen
Journal:  PLoS Pathog       Date:  2017-06-05       Impact factor: 6.823

10.  Gene variation in IL-7 receptor (IL-7R)α affects IL-7R response in CD4+ T cells in HIV-infected individuals.

Authors:  Hans Jakob Hartling; Lars P Ryder; Henrik Ullum; Niels Ødum; Susanne Dam Nielsen
Journal:  Sci Rep       Date:  2017-02-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.